证券代码：603566 证券简称：普莱柯 公告编号：2025-039 普莱柯生物工程股份有限公司关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，经农业农村部审查，批准普莱柯生物工程股份有限公 司（以下简称"公司"）及全资子公司洛阳惠中生物技术有限公司（以下简称"惠中生物"）、洛阳惠中动 物保健有限公司（以下简称"惠中动保"）等单位联合申报的"猫泛白细胞减少症、杯状病毒病、鼻气管 炎三联灭活疫苗（708株+60株+64株）"为新兽药，并于2025年9月29日公示了核发《新兽药注册证书》 （中华人民共和国农业农村部公告第953号）事项。详情如下： 一、新兽药的基本信息 新兽药名称：猫泛白细胞减少症、杯状病毒病、鼻气管炎三联灭活疫苗（708株+60株+64株） 注册分类：三类 主要成分与含量：每头份疫苗中含灭活的猫泛白细胞减少症病毒708株105.7FAID50，含灭活的猫杯状 病毒60株109.0TCID50，含灭活的猫疱疹病毒1型64株107.2TCID5 ...

Core Points - The company, Pulaike, announced the approval of a new veterinary drug by the Ministry of Agriculture and Rural Affairs, which includes a trivalent inactivated vaccine for feline panleukopenia, calicivirus disease, and rhinotracheitis [1] Group 1 - The new veterinary drug is a combination vaccine consisting of strains 708, 60, and 64 [1] - The approval was granted following the review process outlined in the Veterinary Drug Management Regulations and the Veterinary Drug Registration Measures [1] - The new veterinary drug registration certificate was officially issued on September 29, 2025, as per the announcement [1]

证券日报网讯 9月29日晚间，科前生物发布公告称，根据《兽药管理条例》和《兽药注册办法》规定， 经中华人民共和国农业农村部审查，批准公司申报的猪塞内卡病毒病灭活疫苗（HB16株，悬浮培养） 为新兽药，并核发《新兽药注册证书》。 （编辑 任世碧） ...

Group 1 - The core point of the article is that Reap Bio (SZ 300119) held a temporary board meeting on September 28, 2025, to discuss the proposal for the fifth temporary shareholders' meeting of 2025 [1] - For the year 2024, Reap Bio's revenue composition is as follows: 43.12% from veterinary biological products, 33.86% from veterinary drugs, 20.63% from pet supply chain, and 2.38% from other sources [1] - As of the report date, Reap Bio has a market capitalization of 9.7 billion yuan [1] Group 2 - The article mentions a competitive scenario where Farmer's Green Bottle was launched, leading to a significant decline in market share for Yibao, dropping nearly 5 percentage points [1]

Core Viewpoint - The company, Prike (603566.SH), has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug aimed at preventing three feline diseases, marking a significant development in its product offerings [1] Group 1: Product Approval - The new veterinary drug is a trivalent inactivated vaccine for feline panleukopenia, feline calicivirus, and feline infectious respiratory disease [1] - The vaccine was jointly submitted by the company and its wholly-owned subsidiaries, Luoyang Huizhong Biotechnology Co., Ltd. and Luoyang Huizhong Animal Health Co., Ltd. [1] - The new veterinary drug registration certificate was officially issued on September 29, 2025, as per the announcement from the Ministry of Agriculture and Rural Affairs [1] Group 2: Vaccine Efficacy - The vaccine is designed to prevent feline panleukopenia, feline calicivirus disease, and feline infectious respiratory disease [1] - The immune response is expected to develop within 7 days after the second vaccination, with an immunity duration of 12 months [1]

Core Viewpoint - The company, Prike (603566.SH), has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug aimed at preventing three feline diseases, marking a significant advancement in its product offerings [1] Group 1: Product Approval - The new veterinary drug is a trivalent inactivated vaccine for feline panleukopenia, feline calicivirus, and feline infectious respiratory disease [1] - The vaccine was jointly submitted by the company and its wholly-owned subsidiaries, Luoyang Huizhong Biotechnology Co., Ltd. and Luoyang Huizhong Animal Health Co., Ltd. [1] - The new veterinary drug registration certificate was officially issued on September 29, 2025, as per the announcement by the Ministry of Agriculture and Rural Affairs [1] Group 2: Vaccine Efficacy - The vaccine is designed to prevent feline panleukopenia, feline calicivirus disease, and feline infectious respiratory disease [1] - The immune response is expected to develop within 7 days after the second vaccination, with an immunity duration of 12 months [1]

Core Viewpoint - The company, Pulike (603566.SH), has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug, specifically a trivalent inactivated vaccine for cats, which targets feline panleukopenia, calicivirus, and rhinotracheitis [1] Group 1 - The new veterinary drug is a joint application by Pulike and its wholly-owned subsidiaries, Luoyang Huizhong Biotechnology Co., Ltd. and Luoyang Huizhong Animal Health Co., Ltd. [1] - The approval includes the issuance of the New Veterinary Drug Registration Certificate, as announced in the Ministry of Agriculture and Rural Affairs' public notice No. 953 [1] - The vaccine is expected to be publicly available by September 29, 2025 [1]

Core Viewpoint - The Ministry of Agriculture and Rural Affairs has approved the joint application of Qingdao Weilan Biological Co., Ltd. and other units for "Potassium Penicillin V Soluble Powder" as a new veterinary drug of category five, indicating a significant step in addressing the urgent market demand for effective treatments for necrotic enteritis in chickens [1] Group 1: Product Development - The product is specifically designed for the treatment of necrotic enteritis in chickens, a condition that currently lacks effective treatment options [1] - A total investment of 2.8067 million yuan has been made in the research and development of this product [1] - The product is notable for being usable during the laying period, having a short withdrawal period, high safety, and convenient dosage form [1] Group 2: Market Implications - There is a pressing market demand for medications that can be used during the egg-laying period, highlighting the product's potential to fill a significant gap in the market [1] - The issuance of the new veterinary drug certificate reflects the company's innovative capabilities and is expected to contribute to new revenue growth [1] - The product still requires approval of the product registration number before it can be marketed [1]

Core Viewpoint - *ST Green Kang is divesting its photovoltaic film business by selling 100% equity of three subsidiaries to Jiangxi Raoxin New Energy Materials Co., Ltd. for cash, aiming to protect shareholder interests and improve financial health [1][4]. Group 1: Company Background - *ST Green Kang, originally focused on veterinary drug development and sales, shifted to the photovoltaic film industry in 2022 due to persistent losses in its core business [2]. - The company acquired Green Kang Yushan for 95 million yuan, despite its book value being only 160,350 yuan, indicating a significant overvaluation at the time of purchase [2][4]. Group 2: Financial Performance - The company has faced substantial losses, reporting a net loss of 222 million yuan in 2023, which is expected to increase to 445 million yuan in 2024, totaling over 700 million yuan in losses within two and a half years [4][5]. - As of June 2023, *ST Green Kang's debt-to-asset ratio surged to 105.82%, indicating a state of insolvency [5]. Group 3: Industry Context - The photovoltaic film industry experienced a downturn from 2023 to 2024, with oversupply leading to declining prices for POE, EVA, and EPE films, adversely affecting *ST Green Kang's profitability [5][6]. - The company's subsidiaries reported negative gross margins in 2024, with Green Kang Yushan at -19.28%, Green Kang Haining at -35.96%, and Green Kang New Energy at 0.41% [5]. Group 4: Strategic Implications - By divesting the loss-making photovoltaic film business, *ST Green Kang aims to refocus on its core veterinary products, enhancing its profitability and sustainability [7]. - The exit from the photovoltaic sector reflects a broader trend of companies withdrawing from the industry amid significant adjustments, with several other firms also choosing to leave [7][8].

Core Viewpoint - The recent announcement by *ST Lvkang to "sell three wholly-owned subsidiaries for 0 yuan" has raised concerns from the Shenzhen Stock Exchange, highlighting the company's deepening operational crisis and strategic missteps [1][2]. Group 1: Asset Acquisition and Disposal - In January 2023, *ST Lvkang acquired Lvkang Yushan for 95 million yuan, viewing it as a key step into the photovoltaic film sector. However, less than two years later, this and two other subsidiaries were sold for 0 yuan to an affiliated party, Jiangxi Raoxin New Energy [2]. - The acquisition of Lvkang Yushan was based on a valuation of 95.7 million yuan, despite its book value being only 1.6035 million yuan, indicating a nearly 60-fold premium. The company claimed it had a technological advantage and stable orders as a core supplier for JinkoSolar [2]. - Following the acquisition, Lvkang Yushan reported continuous losses, with a projected loss of 203 million yuan in 2024, leading to a total book value of the three subsidiaries being negative 100 million yuan [2][3]. Group 2: Financial Performance and Strategic Failures - Originally focused on veterinary medicine, *ST Lvkang's performance declined, prompting a high-profile pivot to the photovoltaic film sector in 2023, including a 290 million yuan investment in a new production project [3]. - The company's net profit attributable to shareholders showed a downward trend with losses of 122 million yuan in 2022, 222 million yuan in 2023, and an expected 445 million yuan in 2024, totaling nearly 700 million yuan in losses [3]. - The rapid expansion in the photovoltaic sector led to oversupply, and the company failed to adapt, resulting in negative net assets and a warning of delisting risk [3]. Group 3: Related Party Transactions and Shareholder Impact - The 0 yuan transaction with Raoxin New Energy, controlled by the company's major shareholder, has been interpreted as an asset stripping maneuver to offload burdens and avoid delisting [4]. - Although the company claims that the transaction does not harm minority shareholders, the transfer of significant loss-making assets raises questions about whether it genuinely resolves underlying issues or merely conceals risks off-balance sheet [4]. Group 4: Future Challenges and Lessons - Even after shedding photovoltaic assets, *ST Lvkang faces ongoing challenges, including a shrinking core business, insufficient profitability, and tight cash flow [5]. - The company has warned of risks related to changes in its main business structure and potential underperformance in profitability following the transaction [5]. - The case of *ST Lvkang serves as a cautionary tale for companies considering cross-industry ventures, emphasizing the need for careful assessment of industry cycles and internal capabilities to avoid resource misallocation and financial crises [5].